Wealthfront Advisers’s Idexx Laboratories IDXX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.86M | Sell |
13,026
-5,576
| -30% | -$3.13M | 0.01% | 383 |
|
|
2026
Q1 | $10.5M | Buy |
18,602
+1,687
| +10% | +$1.08M | 0.02% | 262 |
|
|
2025
Q4 | $11.4M | Buy |
16,915
+7,438
| +78% | +$5.07M | 0.03% | 231 |
|
|
2025
Q3 | $6.05M | Buy |
9,477
+2,463
| +35% | +$1.49M | 0.01% | 349 |
|
|
2025
Q2 | $3.76M | Buy |
7,014
+468
| +7% | +$224K | 0.01% | 434 |
|
|
2025
Q1 | $2.75M | Buy |
6,546
+428
| +7% | +$186K | 0.01% | 459 |
|
|
2024
Q4 | $2.53M | Sell |
6,118
-1,087
| -15% | -$477K | 0.01% | 474 |
|
|
2024
Q3 | $3.64M | Sell |
7,205
-300
| -4% | -$146K | 0.01% | 379 |
|
|
2024
Q2 | $3.66M | Sell |
7,505
-104
| -1% | -$52.2K | 0.01% | 347 |
|
|
2024
Q1 | $4.11M | Sell |
7,609
-162
| -2% | -$88.5K | 0.01% | 315 |
|
|
2023
Q4 | $4.31M | Buy |
7,771
+1,310
| +20% | +$615K | 0.02% | 274 |
|
|
2023
Q3 | $2.83M | Sell |
6,461
-120
| -2% | -$59.8K | 0.01% | 353 |
|
|
2023
Q2 | $3.31M | Sell |
6,581
-313
| -5% | -$150K | 0.01% | 302 |
|
|
2023
Q1 | $3.45M | Buy |
6,894
+84
| +1% | +$40.2K | 0.02% | 276 |
|
|
2022
Q4 | $2.78M | Buy |
6,810
+2,300
| +51% | +$893K | 0.01% | 312 |
|
|
2022
Q3 | $1.47M | Buy |
4,510
+1,216
| +37% | +$447K | 0.01% | 428 |
|
|
2022
Q2 | $1.16M | Sell |
3,294
-2,312
| -41% | -$943K | 0.01% | 469 |
|
|
2022
Q1 | $3.07M | Buy |
5,606
+1,716
| +44% | +$903K | 0.01% | 302 |
|
|
2021
Q4 | $2.56M | Sell |
3,890
-163
| -4% | -$102K | 0.01% | 337 |
|
|
2021
Q3 | $2.52M | Buy |
4,053
+115
| +3% | +$77.3K | 0.01% | 296 |
|
|
2021
Q2 | $2.49M | Buy |
3,938
+188
| +5% | +$104K | 0.01% | 260 |
|
|
2021
Q1 | $1.83M | Buy |
3,750
+654
| +21% | +$328K | 0.01% | 292 |
|
|
2020
Q4 | $1.55M | Buy |
3,096
+738
| +31% | +$330K | 0.01% | 287 |
|
|
2020
Q3 | $927K | Buy |
2,358
+10
| +0.4% | +$3.7K | 0.01% | 339 |
|
|
2020
Q2 | $775K | Buy |
2,348
+477
| +25% | +$138K | 0.01% | 357 |
|
|
2020
Q1 | $453K | Sell |
1,871
-1,681
| -47% | -$439K | ﹤0.01% | 358 |
|
|
2019
Q4 | $928K | Buy |
3,552
+1,158
| +48% | +$305K | 0.01% | 334 |
|
|
2019
Q3 | $651K | Buy |
2,394
+3
| +0.1% | +$835 | 0.01% | 351 |
|
|
2019
Q2 | $658K | Buy |
2,391
+74
| +3% | +$18.2K | 0.01% | 350 |
|
|
2019
Q1 | $518K | Sell |
2,317
-1,527
| -40% | -$315K | ﹤0.01% | 364 |
|
|
2018
Q4 | $715K | Buy |
+3,844
| New | +$788K | 0.01% | 303 |
|
Other funds holding IDXX
Wealthfront Advisers's IDXX Position: Q2 2026 in Review
Wealthfront Advisers reduced its Idexx Laboratories (IDXX) stake by 30% in Q2 2026, selling an estimated $3.13M and leaving 13,026 shares worth $6.86M. The position accounts for 0.01% of the portfolio, ranked #383.
Wealthfront Advisers first reported a position in IDXX in Q4 2018 and has held it in 31 quarters since. The position peaked at $11.4M in Q4 2025. 1,306 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.
- Wealthfront Advisers held 13,026 shares of Idexx Laboratories worth $6.86M as of Q2 2026.
- Wealthfront Advisers sold 5,576 Idexx Laboratories shares in Q2 2026, an estimated $3.13M.
- Idexx Laboratories made up 0.01% of Wealthfront Advisers's portfolio in Q2 2026, its #383 holding.
- Wealthfront Advisers first reported a position in Idexx Laboratories in Q4 2018 and has held it in 31 quarters since.
- Wealthfront Advisers's Idexx Laboratories position peaked at $11.4M in Q4 2025.
- 1,306 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.
Based on Wealthfront Advisers's 13F filing for Q2 2026, filed 7 Aug 2026.